🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Ivy Brain Tumor Center at Barrow Neurological Institute announced recently a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma. Click here to learn more: ecs.page.link/R7doD

❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ GSK! We're accelerating the Gliofocus Study, a global trial comparing niraparib, a PARP1/2 inhibitor, against TMZ for newly diagnosed MGMT-unmethylated #GBM. 📰: loom.ly/ckeho64

At the Ivy Center, our dedication is to find a cure for brain cancer. On #WorldBrainTumorDay, we continue to push boundaries in brain tumor research to discover new, more effective therapies. Join us in raising awareness in the fight against brain tumors. 🌏🧠

So excited to get these data out finally. It has been such a pleasure working with Roel Verhaak Kevin Johnson and team! Key take aways - CDK4/6i treatment results in cell state change that is reproducible in vitro and no brain penetration or PD effect seen for Everolimus

Congratulations Mylan Blomquist and Nhan Tran Mayo Clinic for your paper on EGFRvIII- and STAT5-dependent sensitivity to Saracatinib treatment in #GBM mdpi.com/1422-0067/25/1…

It has been such a pleasure to work with Amy Ivy Brain Tumor Center over the last five years! She is our go to person when it comes to any data management questions! Looking forward to many more collaborative years, Amy! 👏🏻💪🏼

Next week, we will send off 38 summer research interns BarrowNeurological with a research symposium packed with student presentations, posters and a keynote speaker who has been my mentor for 25 years! I could not be more excited to welcome Dr. Huganir @rhuganir to Barrow!

As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See pubs.acs.org/doi/10.1021/ac…, science.org/doi/10.1126/sc… and perhaps most importantly pubs.acs.org/doi/full/10.10…. Fantastic job!

So great to have three of Ivy Brain Tumor Center researchers be part of this amazing @abta community. An-Chi Tien Charuta Furey, MD and Artak Tovmasyan 👏🏻🧠

🎉 Congratulations to Dr. Nader Sanai, director of the Ivy Center, for being named the 2024 Arizona Bioscience Researcher of the Year! Dr. Sanai will receive this award at the 20th Annual AZBio Awards on Sept. 18. 📰: loom.ly/Ug6S3PE

I had a great time attending and presenting at the CU Anschutz Cancer Biology Graduate Program retreat this weekend. Fantastic talks from the students and faculty. Thank you to the organizers for inviting me Morgan Fox Ellen Bamberg and others. It was great catching up with Diana Cittelly and @mitralabcuamc

Great to hear Douglas Hanahan give the Keynote talk at #SNO2024.

Stop by tonight at An-Chi Tien ‘s poster on our Phase 0/1 trial with 4th generation EGFR inhibitor in rGBM patients #SNO2024 Ivy Brain Tumor Center BarrowNeurological

So honored to get the opportunity to present these data on behalf of our incredible team Ivy Brain Tumor Center BarrowNeurological #SNO2024

.Yoshie Umemura from Ivy Brain Tumor Center presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024

Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025

Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from Ivy Brain Tumor Center. Her work focuses on preclinical drug combination studies in glioma models. #AACR2025

Two posters from Ivy Brain Tumor Center were presented at the AACR annual meeting by An-Chi Tien and Jocelyn Harmon on our ongoing Phase 0/1 trial for EGFR inhibitor (BDTX-1535) in recurrent GBM patients and Factors influencing participant attrition in Phase 0 hybrid trials. #AACR2025.

Fantastic session on Hippo signaling in cancer AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025

Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from Ivy Brain Tumor Center on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025